Briefing · 20 Oct 2026 · figures checked 19 Oct 2026

Topical finasteride online: the price, the trial, and the FDA alert (2026)

Topical finasteride matched the pill for hair count in a 458-man trial while cutting blood DHT roughly half as much. But the product in that trial is not what US clinics sell, and in April 2025 the FDA issued an alert about the compounded versions that are. Here is the evidence, the warning, and what the clinics in our index charge.

Compiled by the Hair Loss Prices index — not written by a clinician. Every price comes from the ledger and carries the date it was read; every clinical claim is sourced at the end of the page. Found something wrong? Tell us and we will fix it and log the fix.

Short answer: in the one large randomised trial, a 0.25% finasteride spray grew almost exactly as much hair as the 1 mg tablet while reducing blood DHT by about half as much. That is the case for the topical. The catch is that the trial product is not sold in the United States: every topical finasteride you can buy from a US telehealth clinic is a compounded formulation, each one different, none FDA-approved — and in April 2025 the FDA issued a safety alert about exactly these products, naming telemedicine platforms and reports of patients being told a topical carried no risk. Published prices in our index run $59 to $99 a month.

What the trial found

The evidence everyone cites is a phase III randomised, double-blind trial published in the Journal of the European Academy of Dermatology and Venereology in 2022. It ran 24 weeks and randomised 458 men: 189 to topical finasteride 0.25% spray, 184 to placebo, and 85 to oral finasteride 1 mg.

• Hair count. In the target area, topical finasteride added 20.2 hairs against 6.7 on placebo, a significant difference. Oral finasteride added 21.1 — a number the authors describe as similar to the topical.
• Blood DHT. This is the point of a topical. Serum DHT fell 34.5% on the spray against 55.6% on the tablet. Placebo barely moved.
• How much drug reaches the blood. Plasma finasteride averaged 48 pg/mL on the topical and 5,029 pg/mL on the tablet — roughly a hundredfold difference.
• Sexual side effects. Treatment-related sexual adverse events ran 2.8% on topical, 3.3% on placebo and 4.8% on oral. Loss of libido was 0.6%, 2.8% and 4.8% respectively. On a formal sexual function questionnaire there was no significant difference from placebo at either 12 or 24 weeks.
• Local effects. The most common treatment-related problems on the topical were itching and redness of the scalp, each 2.2%.

That is a genuinely good result, and it is the basis for every claim you will read that topical finasteride is "as effective, with fewer side effects". Two honest limits: the trial stopped at 24 weeks, so nobody has compared the two over the years you would actually take either; and 85 men on the oral arm is a small comparison group.

The product in that trial is not the product you can buy

This is the part the marketing leaves out, and it matters more than anything else on this page.

The trial tested a single standardised product: finasteride 0.25%, in a defined spray, made to one specification. No such product is approved in the United States. What the clinics in our index sell is compounded — mixed to a prescription by a compounding pharmacy — and every one of them is a different recipe:

• Strut Health sells a five-in-one gel: 0.25% finasteride with up to 7.5% minoxidil, tretinoin and fluocinolone.
• Happy Head sells a topical with up to 8% minoxidil plus finasteride, retinoic acid and hydrocortisone.
• XYON Health sells a proprietary gel of its own.
• Hims and Hers sell a 0.3% finasteride and 6% minoxidil spray or serum.
• Ro sells a compounded spray its own page states is not FDA-approved.

Different concentration, different vehicle, different additional active ingredients. The safety data above was generated by one formulation, and there is no basis for assuming it transfers to another with four extra drugs in it. When a clinic cites the trial next to its own product, it is borrowing evidence it did not earn.

The FDA alert, April 2025

On 22 April 2025 the FDA issued a compounding risk alert on topical finasteride. The substance of it:

• The agency received 32 adverse event reports between 2019 and 2024 involving compounded topical finasteride.
• The events reported included erectile dysfunction, decreased libido, testicular pain, anxiety, depression, suicidal ideation, brain fog, fatigue and insomnia — the same family of effects seen with the oral drug.
• The FDA stated plainly that "There is no FDA-approved topical formulation of finasteride," and that absorption through the skin into the bloodstream is expected.
• In most of those reports, the effects continued after the product was stopped.
• The agency said it was aware of compounders and telemedicine platforms marketing these products, and that some patients reported being told there was no risk because the product was topical.

Thirty-two reports over six years is a small number, and adverse event reporting is voluntary, so it establishes neither a rate nor a cause. It is not a recall and topical finasteride has not been withdrawn. But it is the FDA saying, in writing, that the central selling point of this category — it's topical, so it can't reach you — is not something a prescriber should be telling you.

Both things are true at once: the trial data is good, and the thing being sold to you is not the thing that was tested. Hold both.

What the clinics charge

Prices as published on each clinic's own pages. Topical finasteride on its own is rare; most clinics sell it combined with minoxidil, which is cheaper but means you cannot tell which ingredient is doing what if something goes wrong.

For comparison, the cheapest published oral finasteride subscription in the index is about $20 a month. Topical costs more, in every case, for a drug that is less well established. The dated lists are on the topical finasteride page and the finasteride plus minoxidil page.

Five things to ask before you buy one

1. What exactly is in it, and at what strength? If the clinic will not list every active ingredient and its concentration before you pay, you cannot know what you are putting on your head. One clinic in this index stopped naming its ingredients publicly in 2026.
2. Which pharmacy compounds it? Compounded products are made by a specific pharmacy to a specific standard. You are entitled to know which.
3. Did anyone tell you a topical carries no systemic risk? If so, that is the exact claim the FDA flagged. Absorption through the scalp is expected, not theoretical.
4. Is it bundled with minoxidil, and can you get it separately? Combinations are cheaper and make side effects impossible to attribute.
5. What happens if you want to stop? Terms are quoted on each clinic's cancellation page.

Where to go next

• Cheapest topical finasteride online, with the date each price was read.
• How to get finasteride online: the oral route, and what the label says.
• The price tracker: what every treatment costs across the index this month.

Sources

• Piraccini B.M. et al., "Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial", Journal of the European Academy of Dermatology and Venereology, 2022: hair count, serum DHT, plasma finasteride and adverse event rates. Wiley · PMC full text · PubMed
• US Food and Drug Administration, compounding risk alert, 22 April 2025: "FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products". fda.gov
• Georgetown Medical Review, "Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects", 2024. gmr.scholasticahq.com
• Clinic prices and formulations: each clinic's own pages as recorded in the index, with the date of the last check shown on every price.

This briefing compares published evidence, prices and terms. It is not medical advice: compounded topical finasteride is a prescription product with no FDA-approved labelling, and a licensed clinician decides whether it is right for you.

Prices in this briefing come from the index, last re-checked 24 Oct 2026; the affiliate note on the home page explains what a partner link does and does not change. See the current ledger.